title: A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.
  
  
  METHODS
  Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or donepezil 10 mg/day (n = 32, after 5 mg/day) for 24 weeks. Our primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI).
  
  
  RESULTS
  A total of 24 patients received donepezil completed the study (mean age = 72.0 + 7.5 K-Mini-Mental State Examination [MMSE] = 21.0 + 5.1). After 12 weeks and 24 weeks, patients showed improvements in cognitive function on the SNSB-D compared baseline of 16.29 points at 12 weeks (P < .05) and 12.44 points at 24 weeks (P < .05). Significant improvements were shown in only memory domain, immediate verbal recall and delayed recall tests. Subgroup with better cognitive function (SNSB-D > 100) were more effective in frontal and memory domains than the other subgroup (SNSB-D < 100). Withdrawal rates due to adverse events were very low (4.16%).
  
  
  CONCLUSIONS
  Donepezil-treated patients with Binswanger type subcortical vascular dementia demonstrated significant improvement in cognition compared with baseline, and donepezil was well tolerated.
authors.affiliation: Department of Neurology, Changwon Fatima Hospital, Changwon, GyeongNam, 641-560, South Korea. chkwonj@gmail.com
authors.forename: Jay Cheol
authors.initials: JC
authors.lastname: Kwon
authors.forename: Eung Gyu
authors.initials: EG
authors.lastname: Kim
authors.forename: Jae Woo
authors.initials: JW
authors.lastname: Kim
authors.forename: Oh Dae
authors.initials: OD
authors.lastname: Kwon
authors.forename: Bong Goo
authors.initials: BG
authors.lastname: Yoo
authors.forename: Hyon Ah
authors.initials: HA
authors.lastname: Yi
authors.forename: Nack Cheon
authors.initials: NC
authors.lastname: Choi
authors.forename: Seon Young
authors.initials: SY
authors.lastname: Ahn
authors.forename: Byung Hwa
authors.initials: BH
authors.lastname: Lee
authors.forename: Myong Jin
authors.initials: MJ
authors.lastname: Kang
authors.forename: Dae Seob
authors.initials: DS
authors.lastname: Choi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000473:pathology; D015140:Dementia, Vascular / Q000188:drug therapy* / Q000473:pathology; D000077265:Donepezil; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007189:Indans / Q000008:administration & dosage* / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil